Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is an oncology-focused precision medicine company with a positive outlook due to its extensive small molecule drug discovery and targeted therapy development capabilities, as well as its multiple clinical-stage product candidates. Its potential for commercial success is supported by its plans for NDA submission and potential off-label use of darovasertib for HLA-A*02:01-positive mUM, strong OS data in earlier trials, and high unmet need in this patient population. Risks include clinical and regulatory failure and competition in the mUM market, but the company's focus on HLA+ patients, potential differentiation from current therapies, and positive KOL feedback are reasons for optimism.

Bears say

IDEAYA Biosciences is an oncology-focused precision medicine company with multiple product candidates in clinical and preclinical stages of development. However, the company's stock should be approached with caution due to high potential competition and relatively low financial prospects with an estimated total addressable market of only $250 million for their main product candidate. Additionally, despite positive trial results, the lack of pivotal OS data and a potential off-label use for HLA-A*02:01-positive patients may cause near-term debates and uncertainty about the success and potential market impact of their lead asset darovasertib.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.